4 research outputs found
Myco-Biocontrol of Insect Pests: Factors Involved, Mechanism, and Regulation
The growing demand for reducing chemical inputs in agriculture and increased
resistance to insecticides have provided great impetus to the development of
alternative forms of insect-pest control. Myco-biocontrol offers an attractive
alternative to the use of chemical pesticides. Myco-biocontrol agents are naturally
occurring organisms which are perceived as less damaging to the environment. Their
mode of action appears little complex which makes it highly unlikely that resistance
could be developed to a biopesticide. Past research has shown some promise of the
use of fungi as a selective pesticide. The current paper updates us about the recent
progress in the field of myco-biocontrol of insect pests and their possible mechanism
of action to further enhance our understanding about the biological control of insect
pests
An exploratory study of exits during Cognitive Analytic Therapy (CAT) for depression and a systematic review of CAT for personality disorders
Angiopoietin-1 improves endothelial progenitor cell–dependent neovascularization in diabetic wounds
Increase in the use of inhaled nitric oxide in neonatal intensive care units in England: a retrospective population study
Objective To describe temporal changes in inhaled nitric oxide (iNO) use in English neonatal units between 2010 and 2015.Design Retrospective analysis using data extracted from the National Neonatal Research Database.Setting All National Health Service neonatal units in England.Patients Infants of all gestational ages born 2010–2015 admitted to a neonatal unit and received intensive care.Main outcome measures Proportion of infants who received iNO; age at initiation and duration of iNO use.Results 4.9% (6346/129 883) of infants received iNO; 31% (1959/6346) were born <29 weeks, 18% (1152/6346) 29–33 weeks and 51% (3235/6346)>34 weeks of gestation. Between epoch 1 (2010–2011) and epoch 3 (2014–2015), there was (1) an increase in the proportion of infants receiving iNO: <29 weeks (4.9% vs 15.9%); 29–33 weeks (1.1% vs 4.8%); >34 weeks (4.5% vs 5.0%), (2) increase in postnatal age at iNO initiation: <29 weeks 10 days vs 18 days; 29–33 weeks 2 days vs 10 days, (iii) reduction in iNO duration: <29 weeks (3 days vs 2 days); 29–33 weeks (2 days vs 1 day).Conclusions Between 2010 and 2015, there was an increase in the use of iNO among infants admitted to English neonatal units. This was most notable among the most premature infants with an almost fourfold increase. Given the cost of iNO therapy, limited evidence of efficacy in preterm infants and potential for harm, we suggest that exposure to iNO should be limited, ideally to infants included in research studies (either observational or randomised placebo-controlled trial) or within a protocolised pathway. Development of consensus guidelines may also help standardise practice